DK2942051T3 - Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor - Google Patents

Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor Download PDF

Info

Publication number
DK2942051T3
DK2942051T3 DK15169378.5T DK15169378T DK2942051T3 DK 2942051 T3 DK2942051 T3 DK 2942051T3 DK 15169378 T DK15169378 T DK 15169378T DK 2942051 T3 DK2942051 T3 DK 2942051T3
Authority
DK
Denmark
Prior art keywords
dosage form
weight
pharmaceutical dosage
solid
amino
Prior art date
Application number
DK15169378.5T
Other languages
English (en)
Inventor
Jörg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Berndl
Jörg Breitenbach
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2942051(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK2942051T3 publication Critical patent/DK2942051T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1. Fast farmaceutisk doseringsform til anvendelse ved behandling af HIV, hvilken doseringsform omfatter en fast dispersion, som omfatter mindst en HIV-protease-inhibitor i mindst en farmaceutisk acceptabel vandopløselig polymer og mindst et farmaceutisk acceptabelt ikke-ionisk overfladeaktivt middel, hvor den nævnte HIV-protease-inhibitor omfatter lopinavir, og hvor det farmaceutisk acceptable ikke-ioniske overfladeaktive middel omfatter et overfladeaktivt middel, der har en HLB-værdi på fra 4 til 10.
2. Fast farmaceutisk doseringsform til anvendelsen ifølge krav 1, hvor den faste dispersion er en glasagtig opløsning eller fast opløsning af den mindst ene HIV-protease-inhibitor.
3. Fast farmaceutisk doseringsform til anvendelse ifølge krav 1 eller krav 2, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, har en HLB-værdi på fra 7 til 9.
4. Fast farmaceutisk doseringsform til anvendelse ifølge krav 1 eller krav 2, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, er en sorbitanfedtsyremonoester.
5. Fast farmaceutisk doseringsform til anvendelsen ifølge krav 4, hvor sorbitanfedtsyremonoesteren er valgt blandt sorbitanmonolaurat, sorbitanmonooleat, sorbitanmonopalmitat og sorbitanstearat.
6. Fast farmaceutisk doseringsform til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den farmaceutisk acceptable vandopløselige polymer har en Tg på mindst 50 °C.
7. Fast farmaceutisk doseringsform til anvendelsen ifølge krav 6, hvor den farmaceutisk acceptable vandopløselige polymer har en Tg på fra 80 til 180 °C.
8. Fast farmaceutisk doseringsform til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den farmaceutisk acceptable vandopløselige polymer omfatter en homopolymer eller copolymer af N-vinylpyrrolidon.
9. Fast farmaceutisk doseringsform til anvendelse ifølge krav 8, hvor den farmaceutisk acceptable vandopløselige polymer omfatter en copolymer af N-vinylpyrrolidon og vinylacetat.
10. Fast farmaceutisk doseringsform til anvendelse ifølge et hvilket som helst af de foregående krav, hvilken doseringsform indeholder mindst ét additiv der er udvalgt blandt strømningsregulatorer, smøremidler, fyldmidler og sprængmidler.
DK15169378.5T 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor DK2942051T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form
EP10181264.2A EP2258345B1 (en) 2003-08-28 2004-08-23 Solid pharmaceutical dosage form comprising an HIV protease inhibitor solid dispersion

Publications (1)

Publication Number Publication Date
DK2942051T3 true DK2942051T3 (da) 2018-05-07

Family

ID=34217089

Family Applications (5)

Application Number Title Priority Date Filing Date
DK10181264.2T DK2258345T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor
DK15169378.5T DK2942051T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor
DK10181268.3T DK2258346T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor
DK10181250.1T DK2258344T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir
DK04816820.7T DK1663183T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende ritonavir

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10181264.2T DK2258345T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK10181268.3T DK2258346T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor
DK10181250.1T DK2258344T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir
DK04816820.7T DK1663183T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende ritonavir

Country Status (31)

Country Link
US (1) US20050048112A1 (da)
EP (6) EP1663183B9 (da)
JP (6) JP4815348B2 (da)
KR (5) KR101132602B1 (da)
CN (5) CN101919858B (da)
AT (1) ATE516017T1 (da)
AU (3) AU2004283087C1 (da)
CA (2) CA2689639C (da)
CR (3) CR8256A (da)
CY (5) CY1111981T1 (da)
DK (5) DK2258345T3 (da)
EA (4) EA201890737A3 (da)
EC (1) ECSP066397A (da)
ES (5) ES2399810T3 (da)
HK (4) HK1094766A1 (da)
HR (1) HRP20110555T1 (da)
HU (3) HUE031153T2 (da)
IL (3) IL173939A (da)
ME (2) ME00130B (da)
MX (2) MXPA06002346A (da)
NO (3) NO330282B1 (da)
NZ (2) NZ579622A (da)
PL (5) PL2942051T3 (da)
PT (5) PT2258344E (da)
RS (2) RS57663B1 (da)
SG (3) SG179401A1 (da)
SI (5) SI2258346T1 (da)
TW (1) TWI342221B (da)
UA (1) UA85564C2 (da)
WO (1) WO2005039551A2 (da)
ZA (3) ZA200801362B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
AU2006326130B2 (en) * 2005-12-14 2011-09-22 F. Hoffmann-La Roche Ag HCV prodrug formulation
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
AU2007283196A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
HUE029842T2 (en) 2007-02-23 2017-04-28 Gilead Sciences Inc Modulation of pharmacokinetic parameters of therapeutic agents
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
EP2444070A1 (en) * 2008-02-28 2012-04-25 Abbott Laboratories Tablets
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
UA106878C2 (uk) * 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
US20120121722A1 (en) 2008-12-18 2012-05-17 Anup Avijit Choudhury Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
EP2279728A1 (en) 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2829186A1 (en) * 2011-03-07 2012-09-13 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
US20140206717A1 (en) * 2011-08-16 2014-07-24 John Higgins Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
CA2866206A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
ES2586912T3 (es) * 2012-03-07 2016-10-19 Ratiopharm Gmbh Forma de dosificación que comprende lopinavir no cristalino y ritonavir cristalino
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048782A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
WO2019166834A1 (en) * 2018-03-02 2019-09-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
US12031128B2 (en) 2021-04-07 2024-07-09 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
KR100815412B1 (ko) 1999-06-04 2008-03-20 아보트 러보러터리즈 개선된 약제학적 제형
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
MXPA02004739A (es) 1999-11-12 2003-01-28 Abbott Lab Formulaciones farmaceuticas de dispersion solida.
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
EP2112925A4 (en) 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS

Also Published As

Publication number Publication date
PT2258345T (pt) 2017-01-20
EP2258345A3 (en) 2011-01-19
ES2653762T3 (es) 2018-02-08
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
EP2258344A3 (en) 2011-01-19
HK1145969A1 (en) 2011-05-13
SG145690A1 (en) 2008-09-29
NO334418B1 (no) 2014-03-03
EP2258344A2 (en) 2010-12-08
NO20100367L (no) 2006-05-29
SI2258345T1 (sl) 2017-01-31
IL254581A0 (en) 2017-11-30
DK2258345T3 (da) 2017-01-16
PL2258344T3 (pl) 2013-04-30
PT2942051T (pt) 2018-04-23
RS20181262A1 (sr) 2019-02-28
EP1663183B1 (en) 2011-07-13
RS20060140A (en) 2008-09-29
WO2005039551A2 (en) 2005-05-06
UA85564C2 (ru) 2009-02-10
KR101563222B1 (ko) 2015-10-26
ES2367173T3 (es) 2011-10-31
SG179401A1 (en) 2012-04-27
ES2399810T3 (es) 2013-04-03
EA200600473A1 (ru) 2006-10-27
AU2010238573A1 (en) 2010-11-18
KR20110122771A (ko) 2011-11-10
MEP17608A (en) 2010-06-10
MX358033B (es) 2018-08-02
CR20120662A (es) 2013-03-13
CN101919858B (zh) 2013-10-30
EP3354261A1 (en) 2018-08-01
KR20060121837A (ko) 2006-11-29
SI2258346T1 (sl) 2017-12-29
PL1663183T3 (pl) 2011-10-31
EA011924B1 (ru) 2009-06-30
JP5395125B2 (ja) 2014-01-22
CN105106104A (zh) 2015-12-02
EA201890737A2 (ru) 2018-08-31
KR20140046078A (ko) 2014-04-17
EP1663183A2 (en) 2006-06-07
AU2004283087B2 (en) 2007-09-20
AU2007249115B2 (en) 2010-08-12
JP2011126898A (ja) 2011-06-30
EA200900292A1 (ru) 2009-06-30
EA020992B1 (ru) 2015-03-31
NO335326B1 (no) 2014-11-10
US20050048112A1 (en) 2005-03-03
HRP20110555T1 (hr) 2011-09-30
CY1111981T1 (el) 2015-11-04
KR101281994B1 (ko) 2013-07-04
ZA200801362B (en) 2009-03-25
ZA200601718B (en) 2009-11-25
TWI342221B (en) 2011-05-21
JP2018035163A (ja) 2018-03-08
NZ579622A (en) 2011-01-28
KR101457967B1 (ko) 2014-11-07
RS57663B1 (sr) 2018-11-30
EP1663183B9 (en) 2012-06-13
CY1113596T1 (el) 2016-06-22
CN102772380A (zh) 2012-11-14
CA2689639A1 (en) 2005-05-06
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
EP2258346A3 (en) 2011-01-19
EA201890737A3 (ru) 2019-01-31
HUE035985T2 (hu) 2018-06-28
CY1119651T1 (el) 2018-04-04
PL2942051T3 (pl) 2018-07-31
JP5498411B2 (ja) 2014-05-21
EP2258345A2 (en) 2010-12-08
EA033224B1 (ru) 2019-09-30
ZA200801361B (en) 2011-11-30
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
AU2010238573B2 (en) 2012-12-13
CR8256A (es) 2008-01-11
CY1118505T1 (el) 2017-07-12
PT1663183E (pt) 2011-08-25
ECSP066397A (es) 2006-08-30
HK1257502A1 (zh) 2019-10-25
HK1094766A1 (en) 2007-04-13
ES2666390T3 (es) 2018-05-04
IL173939A (en) 2017-03-30
SI2942051T1 (en) 2018-06-29
AU2007249115A1 (en) 2008-01-10
PL2258345T3 (pl) 2017-03-31
KR20120054666A (ko) 2012-05-30
PL2258346T3 (pl) 2018-01-31
SG10201507902UA (en) 2015-10-29
CR20120661A (es) 2013-03-13
DK1663183T3 (da) 2011-08-29
NO20131743L (no) 2006-05-29
AU2004283087C1 (en) 2008-04-24
CA2536638C (en) 2010-04-06
JP4815348B2 (ja) 2011-11-16
NO330282B1 (no) 2011-03-21
CA2536638A1 (en) 2005-05-06
HK1217298A1 (zh) 2017-01-06
CN101919858A (zh) 2010-12-22
WO2005039551A3 (en) 2006-08-03
EA201301045A1 (ru) 2014-05-30
MXPA06002346A (es) 2006-05-19
CN102772380B (zh) 2015-08-19
CN1901884A (zh) 2007-01-24
IL207260A (en) 2017-10-31
NZ545499A (en) 2009-11-27
EP2942051A1 (en) 2015-11-11
RS59969B1 (sr) 2020-03-31
JP2016094433A (ja) 2016-05-26
ME00130B (me) 2010-10-10
ES2608720T3 (es) 2017-04-12
EP2258345B1 (en) 2016-09-21
JP5903413B2 (ja) 2016-04-13
KR20150044031A (ko) 2015-04-23
JP2013241460A (ja) 2013-12-05
JP2007504142A (ja) 2007-03-01
HUE038792T2 (hu) 2018-11-28
KR101132602B1 (ko) 2012-04-06
SI2258344T1 (sl) 2013-03-29
PT2258344E (pt) 2013-02-18
EP2258344B1 (en) 2012-11-14
HUE031153T2 (en) 2017-07-28
DK2258344T3 (da) 2013-01-02
CY1120138T1 (el) 2018-12-12
EP2258346A2 (en) 2010-12-08
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
JP2011236232A (ja) 2011-11-24
NO20061342L (no) 2006-05-29
AU2004283087A1 (en) 2005-05-06
PT2258346T (pt) 2017-10-24
ATE516017T1 (de) 2011-07-15
IL173939A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
DK2942051T3 (da) Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor
US8399015B2 (en) Solid pharmaceutical dosage form
AU2013201423B2 (en) Solid pharmaceutical dosage form